Mochi Health vs OrderlyMeds: November 2026 prices compared
As of November 20, 2026, from each program’s own page: on compounded tirzepatide, only OrderlyMeds prints a comparable month-to-month price, $299 a month; Mochi Health shows only a starting-dose or coupon figure (from $139, $90 starting dose + $49 membership on a 12-month plan), so no like-for-like comparison is possible.
Released · Last reviewed · how we verify
On compounded semaglutide, only OrderlyMeds prints a comparable month-to-month price, $149 a month; Mochi Health shows only a starting-dose or coupon figure (from $109, $60 starting dose + $49 membership on a 12-month plan), so no like-for-like comparison is possible.
Mochi Health and OrderlyMeds, measure by measure
| Measure | Mochi Health | OrderlyMeds |
|---|---|---|
| Tirzepatide, month to month | from $169 (per month, starting-dose price) | $299 (per month) |
| Tirzepatide, lowest printed | $139 ($90 starting dose + $49 membership on a 12-month plan) | $149 (2-month new-customer offer, $299) |
| Semaglutide, month to month | from $139 (per month, starting-dose price) | $149 (per month) |
| Semaglutide, lowest printed | $109 ($60 starting dose + $49 membership on a 12-month plan) | $74 (2-month new-customer offer, $149) |
| Dose pricing | priced by dose or not stated | same price at every dose |
| Membership or program fee | about $79 a month | none |
| Computed score | 8 of 40 (position 18 of 27) | 27.9 of 40 (position 6 of 27) |
| FDA warning letters | none listed | 728291 (2026-06-08) |
| November 20 read | first-party read, changed | first-party read |
Strengths and limitations: which fits whom
Mochi Health prices by dose, so its printed figure covers the first months; budget for a higher maintenance-dose price. OrderlyMeds prints one price at every dose with no membership, so a dose increase does not change the bill. Compounded tirzepatide and semaglutide are not FDA-approved and are not the same products as Zepbound or Wegovy; a licensed clinician decides whether either is appropriate for you.
What changed since August
The first version of this comparison used captures from August 5–10, 2026. The November 20 re-read replaces them; the August figures are kept below as history, dated.
| Program | Medication | August 5–10, 2026 | November 20, 2026 |
|---|---|---|---|
| Mochi Health | tirzepatide | — | from $169 |
| Mochi Health | semaglutide | — | from $139 |
| OrderlyMeds | tirzepatide | — | $299 |
| OrderlyMeds | semaglutide | — | $149 |
Regulatory record
FDA’s warning-letter index lists warning letter 728291 (dated June 8, 2026, subject “False & Misleading Claims/Misbranded (Telehealth)”) to OrderlyMeds; no close-out letter is listed. A warning letter is FDA’s formal notice of alleged violations, not a recall, ban or court finding.
Frequently asked
Which is cheaper, Mochi Health or OrderlyMeds?
On compounded tirzepatide, only OrderlyMeds prints a comparable month-to-month price, $299 a month; Mochi Health shows only a starting-dose or coupon figure (from $139, $90 starting dose + $49 membership on a 12-month plan), so no like-for-like comparison is possible. On compounded semaglutide, only OrderlyMeds prints a comparable month-to-month price, $149 a month; Mochi Health shows only a starting-dose or coupon figure (from $109, $60 starting dose + $49 membership on a 12-month plan), so no like-for-like comparison is possible.
Do Mochi Health and OrderlyMeds charge a membership fee?
Mochi Health: about $79 a month on top of medication; OrderlyMeds: no membership fee. This site folds any required recurring fee into the all-in figures above, so the comparison already counts it.
Are Mochi Health and OrderlyMeds medications FDA-approved?
Compounded tirzepatide and semaglutide from any telehealth program are not FDA-approved and are not the same products as Zepbound, Mounjaro, Wegovy or Ozempic. Brand medications sold through a manufacturer or a brand route are FDA-approved. Ask each program which pharmacy fills the prescription.
Sources
- FDA: Concerns with unapproved GLP-1 drugs used for weight loss (content current as of October 1, 2026; read November 20, 2026)
- Federal Register 91 FR 23431: proposed 503B bulks-list decision for semaglutide, tirzepatide and liraglutide (May 1, 2026; no final notice found as of November 20, 2026)
- Zepbound (tirzepatide) prescribing information on DailyMed (read November 20, 2026)
- Wegovy (semaglutide) prescribing information on DailyMed (read November 20, 2026)
- Mochi Health pricing page (read November 20, 2026)
- OrderlyMeds pricing page (read November 20, 2026)
- FDA warning letter 728291 to OrderlyMeds (dated 2026-06-08, posted 2026-06-16)